Tewksbury, Massachusetts-based Corvia Medical earmarked the funds to support a confirmatory trial to build upon data and learnings from the clinical trial of its Corvia atrial shunt in heart failure patients with preserved (HFpEF) or mildly reduced HFmrEF ejection fraction.
Corvia’s atrial shunt is placed via catheter between the left and right atria to create a passage through which blood is allowed to flow from the high-pressure left atrium to the lower-pressure right atrium. potentially reducing HF symptoms and events and improving quality of life.
In April, Corvia published positive results from its global, phase III Reduce LAP-HF II randomized trial for the atrial shunt, having just two months prior reported that results from the same trial demonstrated that the atrial shunt device did not reduce heart failure ra…